Stifel Financial Corp Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN)

Stifel Financial Corp grew its position in Precigen, Inc. (NASDAQ:PGEN) by 94.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,200 shares of the biotechnology company’s stock after buying an additional 15,680 shares during the period. Stifel Financial Corp’s holdings in Precigen were worth $30,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. ClariVest Asset Management LLC lifted its holdings in Precigen by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 13,752 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 13,823 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Precigen by 10.2% during the third quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 15,525 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Precigen by 40.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 16,486 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 18,097 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Trading Up 28.0 %

Shares of PGEN opened at $0.93 on Tuesday. The firm has a market capitalization of $272.37 million, a price-to-earnings ratio of -1.69 and a beta of 1.71. The firm’s fifty day simple moving average is $0.83 and its 200-day simple moving average is $1.11. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $1.93.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Precigen in a research note on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Precigen presently has an average rating of “Hold” and an average price target of $7.00.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.